冷冻活检与钳夹活检在支气管镜肺活检中的比较:FROSTBITE-2随机临床试验
这项多中心随机临床试验纳入500例拟行经支气管活检的患者,比较1.1毫米冷冻探针与2.0毫米钳夹的诊断率。肺结节或肿块及肺移植亚组中冷冻探针诊断率亦显著更高,而弥漫性肺实质疾病组无显著差异。
要点
- 1.1毫米冷冻探针经支气管活检诊断率显著优于2.0毫米钳夹。
- 肺结节或肿块及肺移植患者中冷冻探针诊断率显著更高。
- 弥漫性肺实质疾病患者中两种方法诊断率无显著差异。
核心结论
- 在肺结节或肿块、肺移植及弥漫性肺实质疾病患者中,1.1毫米冷冻探针经支气管肺活检的诊断率显著高于2.0毫米钳夹。
研究设计与样本
- 开放标签、结局评估者设盲的多中心随机临床试验,在美国9个医学中心纳入500例年龄≥18岁拟行经支气管活检的患者,1:1随机分配至1.1毫米冷冻探针组(n=250)或2.0毫米钳夹组(n=250)。
主要发现
- 钳夹组有4例(1.6%)需置胸管的气胸,冷冻探针组无;两组均无显著出血或呼吸衰竭事件。
临床怎么用
- 对于肺结节或肿块及肺移植患者的经支气管活检,可优先考虑使用1.1毫米冷冻探针以提高诊断率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bronchoscopic biopsy is conventionally performed with forceps, which can result in small specimen sizes and poor specimen quality due to crush artifact. Cryoprobe use localizes freezing at the probe tip, enabling retrieval of larger, more intact biopsy specimens. OBJECTIVE: To evaluate the diagnostic yield of a 1.1-mm cryoprobe for transbronchial biopsy. DESIGN, SETTING, AND PARTICIPANTS: This open-label, outcome assessor-masked, multicenter randomized clinical trial included 500 patients aged 18 years or older scheduled to undergo transbronchial biopsy for lung nodules or masses, lung transplant, or diffuse parenchymal lung disease. The trial was conducted in 9 US medical centers and enrolled patients between February 27, 2023, and September 11, 2024. The date of last follow-up was October 12, 2024. INTERVENTION: Patients were randomized 1:1 to transbronchial biopsy using a 1.1-mm cryoprobe (n = 250) or 2.0-mm forceps (n = 250). MAIN OUTCOMES AND MEASURES: The primary outcome was diagnostic yield, defined as the percentage of patients for whom the transbronchial biopsy sample led to a specific diagnosis based on histologic examination. Of the 8 prespecified secondary analyses, key secondary analyses were the diagnostic yield for each of the 3 conditions (lung nodules or masses, lung transplant, and diffuse parenchymal lung disease) and complication rates. RESULTS: Of 774 patients assessed for eligibility, 609 provided consent, 500 were randomized, and 490 were included in the primary analysis; the mean age was 62.6 years (SD, 12.7 years) and 252 of 500 (50.4%) were male. The primary outcome of diagnostic yield was significantly higher in patients randomized to transbronchial biopsy with cryoprobes vs forceps (217 of 245 [88.6%] vs 193 of 245 [78.8%]; absolute difference, 9.8%; 95% CI, 3.3%-16.3%; P = .003). For the key secondary analyses, compared with that of forceps, the diagnostic yield of cryoprobes was significantly higher among patients with pulmonary nodules or masses (79 of 95 [83.2%] vs 68 of 97 [70.1%]; absolute difference, 13.1%; 95% CI, 1.0%-24.6%; P = .04) and lung transplant (120 of 125 [96.0%] vs 110 of 124 [88.7%]; absolute difference, 7.3%; 95% CI, 0.6%-14.4%; P = .03) but did not differ significantly in diffuse parenchymal lung disease (18 of 25 [72.0%] vs 15 of 24 [62.5%]; absolute difference, 9.5%; 95% CI, -16.0% to 33.6%; P = .55). For the secondary safety analysis, there were 4 pneumothoraces requiring chest tube placement in the forceps group (1.6%) vs none in the cryoprobe group; no patients experienced significant bleeding or respiratory failure events. CONCLUSIONS AND RELEVANCE: Transbronchial lung biopsy performed with a 1.1-mm cryoprobe had a significantly higher diagnostic yield compared with 2.0-mm forceps in a group of patients with lung nodules or masses, lung transplant, and diffuse parenchymal lung disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05751278.
引用
- Thiboutot J, Kapp CM, Illei P, et al. Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42149700. doi:10.1001/jama.2026.7908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。